Triple negative breast cancer (TNBC) accounts for approximately 10–20% of breast cancer cases and lacks expression of the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2. This evidence concerns the gene ERBB2 and breast carcinoma.